46
Participants
Start Date
March 10, 2014
Primary Completion Date
December 18, 2024
Study Completion Date
December 18, 2024
Trametinib
Given PO
Moffitt Cancer Center, Tampa
Ohio State University Comprehensive Cancer Center, Columbus
Wayne State University/Karmanos Cancer Institute, Detroit
University of Chicago Comprehensive Cancer Center, Chicago
Washington University School of Medicine, St Louis
M D Anderson Cancer Center, Houston
University of California Davis Comprehensive Cancer Center, Sacramento
Rutgers Cancer Institute of New Jersey, New Brunswick
BCCA-Vancouver Cancer Centre, Vancouver
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
University Health Network-Princess Margaret Hospital, Toronto
National Cancer Institute (NCI)
NIH